Higher levels of transferrin saturation were proven to increase the risk of NAFLD (OR: 1.18, 95%CI: 1.08—1.29), alcoholic liver disease (OR: 1.18, 95%CI: 1.00—1.39), and liver cancer (OR: 1.42, 95%CI: 1.17—1.72), but decrease the risk of esophageal cancer (OR: 0.83, 95%CI: 0.71—0.97). This evidence concerns the gene TF and metabolic dysfunction-associated steatotic liver disease.